Log In
Print
BCIQ
Print
Print this Print this
 

Avonex, Interferon beta-1a

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionInterferon (IFN) beta-1a
Molecular Target Type I interferon (IFN) receptor
Mechanism of ActionImmune modulation
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS); Treat primary progressive multiple sclerosis (PPMS); Treat relapsing multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation
Partner UCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today